Astrana Health (ASTH): Buy, Sell, or Hold Post Q2 Earnings?

Astrana Health (ASTH) stock has risen 35.1% in six months, reaching $37.03. The company, formerly Apollo Medical Holdings, reported 40.2% revenue growth and 11.6% EPS growth over five years. However, its return on invested capital has declined. The stock trades at 11.1× forward P/E. Analysts debate its valuation and potential for new investments.

Original reporting
Published Oct 8, 2026, 2:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 2:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Astrana Health (ASTH): Buy, Sell, or Hold Post Q2 Earnings? — source image
Decision brief

The 30-second read

$ASTHNeutralLow
01

Why it matters

Provides no new information; serves as a promotional piece with historical data only.

02

Market read

Low relevance; opinion/marketing content without fresh catalyst.

03

What to watch

Upcoming earnings release or potential regulatory updates could change the outlook, but are not covered here.

Relevance 4/10Novelty 2/10Timing: none

Background

The article reviews Astrana Health's past performance, growth rates, and valuation, ending with a call to view a free research report.

Company-level read

Ticker impact

$ASTHNeutralLow confidence
Context

Article discusses Astrana Health's performance and valuation but provides no new data or catalyst.

Expected impact

likely little impact as no new catalyst is presented

Evidence & confidence

The piece recycles historical growth figures and offers a buy/sell/hold opinion without new events.

Market effects

Reinforces general positive narrative for the US healthcare sector.

Minimal effect on regional markets; limited interest beyond existing healthcare investors.

Low global relevance as content is US‑focused and lacks new data.

Counterpoint

Without new data, investors may remain cautious and avoid taking a position based solely on this article.

Key entities

  • Astrana Health

    US‑listed healthcare platform (NASDAQ:ASTH) discussed in the article.

Related articles

$ASTHHighAI 8/10

Astrana Health Earnings Call Highlights Growth and Deleveraging

Astrana Health (ASTH) reported Q3 revenue of $1.02B (+7% YoY) and adjusted EBITDA of $77.2M (+13% YoY). The company highlighted organic growth, debt reduction, and favorable Medicare trends. Management maintained full-year guidance, expecting revenue of $3.9B-$4B and adjusted EBITDA of $261M-$274M. Challenges include Medicaid pressure and seasonality.

$ASTHMed

Astrana Health 3Q 2026: Revenue $1.02B, EPS $0.26 — 10-Q Summary

Astrana Health reported 3Q 2026 revenue of $1.02B, up 7% YoY, and net income of $13.0M, compared to $373K last year. Growth was driven by 9% increase in capitation revenue. Care Partners saw 8% revenue growth and 94% operating income rise, while Care Delivery revenue increased 5% but operating loss widened. Care Enablement revenue rose 5% with 4% higher operating income. Astrana managed 29 IPAs and 1.5M patients as of September 30, 2026.

$ASTHMed

Astrana Health Inc (ASTH) (Q3 2026) Earnings Call Highlights: Record Revenue and EBITDA

Astrana Health Inc (ASTH) reported Q3 2026 earnings, highlighting record revenue and EBITDA growth. CEO Brandon Sim discussed Medicaid membership attrition, Medicare Advantage dynamics, and care enablement business momentum. The company expects mid-teens EBITDA growth despite Medicaid headwinds. A cybersecurity incident is under investigation, and a new 'premiums at risk' disclosure was introduced for ACO business transparency.

$ASTHHighAI 8/10

Astrana Health (ASTH) Q3 2026 Earnings Call Transcript

Astrana Health (ASTH) reported Q3 2026 revenue of $1.02B (+7% YoY) and adjusted EBITDA of $77.2M (+13% YoY). Membership grew to 1.5M, with Medicare Advantage increasing organically. The company completed acquisitions and partnerships, expanding its presence. Medical cost trends were slightly better than expected, with Texas operations performing ahead of plan. Free cash flow reached $105M, and net leverage was reduced to 2.2x.

$ASTHMed

Astrana Health Q3 Earnings Call Highlights

Astrana Health reported 1.5 million members under management, with Medicare Advantage growth offsetting Medicaid attrition. The company expects Medicaid membership to decline 10-15% in 2027, impacting adjusted EBITDA. Medical cost trends were slightly better than expected, with Medicare Advantage margins stable. Astrana plans 82% of capitation revenue from full-risk arrangements by 2026 and completed acquisitions and partnerships.